Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Not Applicable

Completed

• Conditions: Schizophrenia; Obsessive Compulsive Disorder
• Interventions: Drug: Ziprasidone

• Registration Number: NCT00229385
• Lead Sponsor: Sheba Medical Center

Brief Summary

Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-09-28
• Study First Submitted QC: 2005-09-28
• Study First Posted: 2005-09-29
• Study Start: 2006-01
• Primary Completion: 2008-04
• Study Completion: 2010-04
• Status Verified: 2013-12
• Last Update Submitted: 2013-12-30
• Last Update Posted: 2013-12-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Diagnosis of Schizophrenia and OCD for at least 6 months
• Minimum score of 14 on YBOCS
• Minimum score of 60 on PANSS
• Diagnosis of Schizophrenia without OC symptoms

Exclusion Criteria

• Patients who are already being treated with ziprasidone
• Diagnosis of schizophreniform disorder
• Organic brain syndrome, mental retardation and pervasive developmental disorder
• Patients having any significantly cardiovascular illness or electrolyte imbalance

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Ziprasidone	-
2	Ziprasidone	-

Primary Outcome Measures

Name	Time	Method
YBOCS	8 weeks

Trial Locations

Locations (1)

Chaim Sheba Medical Center; 🇮🇱 Ramat-Gan, Israel